BioCentury
ARTICLE | Company News

Andrx, Hoechst Marion Roussel Inc. cardiovascular news

June 14, 1999 7:00 AM UTC

Hoechst and its Carderm Capital L.P. affiliate agreed to dismiss their 1996 lawsuit alleging that ADRX's generic version of Hoechst's Cardizem CD diltiazem infringed Hoechst's patent covering the delayed release component of the hypertension and angina product (see BioCentury, Sept. 22, 1997).

The dismissal stems from ADRX's 1998 amendment of its ANDA that involved reformulating the controlled release profile of the original compound. The amended ANDA has received FDA approval and ADRX plans to launch the product this month. ...